Drug Profile
Renzapride - Atlantic Healthcare
Alternative Names: ATL-1251; AZM 112; BRL-24924; Renzapride hydrochlorideLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Alizyme; Atlantic Healthcare; GlaxoSmithKline
- Class Antifibrotics; Antiparkinsonians; Benzamides; Gastrokinetics; Heterocyclic bicyclo compounds; Irritable bowel syndrome therapies; Skin disorder therapies; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists; Serotonin 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Cystic fibrosis; Gastroparesis; Parkinson's disease; Systemic scleroderma
- Discontinued Diabetic gastroparesis; Gastro-oesophageal reflux; Irritable bowel syndrome
Most Recent Events
- 28 Nov 2023 Renzapride is still in phase I trials for Cystic-fibrosis in United Kingdom (Atlantic Healthcare pipeline, November 2023)
- 28 Nov 2023 Renzapride is still in phase I trials for Systemic-scleroderma in United Kingdom (Atlantic Healthcare pipeline, November 2023)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Cystic-fibrosis in United Kingdom (PO)